GFM
SUPN icon

GF Fund Management’s Supernus Pharmaceuticals SUPN Stock Holding History

GF Fund Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56.6K Sell
1,216
-72
-6% -$3.46K ﹤0.01% 377
2026
Q1 		$66.6K Buy
1,288
+162
+14% +$8.25K ﹤0.01% 370
2025
Q4 		$56K Sell
1,126
-80
-7% -$3.89K ﹤0.01% 397
2025
Q3 		$57.6K Sell
1,206
-207
-15% -$8.34K ﹤0.01% 379
2025
Q2 		$44.5K Hold
1,413
– – ﹤0.01% 426
2025
Q1 		$46.3K Buy
1,413
+254
+22% +$9K ﹤0.01% 429
2024
Q4 		$41.9K Buy
+1,159
New +$40.8K ﹤0.01% 405

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

GF Fund Management's SUPN Position: Q2 2026 in Review

GF Fund Management reduced its Supernus Pharmaceuticals (SUPN) stake by 5.6% in Q2 2026, selling an estimated $3.46K and leaving 1,216 shares worth $56.6K. The position accounts for ﹤0.01% of the portfolio, ranked #377.

GF Fund Management first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $66.6K in Q1 2026. 335 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • GF Fund Management held 1,216 shares of Supernus Pharmaceuticals worth $56.6K as of Q2 2026.
  • GF Fund Management sold 72 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.46K.
  • Supernus Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #377 holding.
  • GF Fund Management first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Supernus Pharmaceuticals position peaked at $66.6K in Q1 2026.
  • 335 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.